Sign inJoin waitlistJoin the waitlist

Upendra Hegde

Chief Medical Oncologist, Melanoma and Cutaneous Oncology; and Head and Neck Cancer/Oral Oncology · University of Connecticut School of Medicine

Credentials: · · ·

History

Melanoma and Cutaneous Oncology; and Head and Neck Cancer/Oral Oncology Division · University of Connecticut School of Medicine
Present
University of Connecticut School of Medicine
Present
University of Connecticut School of Medicine
Present

Hematology
1991–1992
Internal Medicine
1988–1991
Doctor of Medicine
1984–1988

Research

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
The Lancet Oncology · 2016 · 837 citations
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role…
Blood · 2005 · First of 11 authors · 284 citations
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Journal of Clinical Oncology · 2008 · 248 citations

Jane Grant-Kels
7 papers
Wyndham Wilson
6 papers
Amit Mahajan
3 papers
Andrew Salner
3 papers
Elaine Jaffe
3 papers
Harriet Kluger
3 papers
Justine Cohen
3 papers · 1 as a fellow
Mario Sznol
3 papers
Sarah Goldberg
3 papers
Veronica Chiang
3 papers
Azra Raza
2 papers
James Yu
2 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $2.5K · University of Connecticut Sch of Med/Dnt
2004–2005

Clinical trials

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2029